(160) found FGFR1 gene amplification and increased expression of Fibroblast Growth Factor 2 (FGF2) in NSCLC patients resistant to osimertinib, suggesting a potential association between the FGFR1 signaling pathway and acquired resistance to osimertinib. This evidence concerns the gene FGFR1 and non-small cell lung carcinoma.